Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
ViaCyte Inc.’s portfolio concerns Biotechnology & Pharmaceuticals and has 1 pending office action. The record shows 1 distinct examiner and 1 distinct art unit, so the pending prosecution activity is centered in one examination setting. That concentration can simplify docket review and help counsel maintain a focused response strategy.
FOX, ALLISON M is the busiest examiner, with 1 pending matter. The available data does not show examiner or art-unit dispersion, so the practical priority is direct analysis of the current action and alignment of any claim amendments with the biotechnology and pharmaceutical subject matter under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOX, ALLISON M | 1 | 71.0% | +35.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18416646 | CELL ENCAPSULATION DEVICE COMPRISING A PANCREATIC PROGENITOR CELL POPULATION | FOX, ALLISON M | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18416646 | CELL ENCAPSULATION DEVICE COMPRISING A PANCREATIC PROGENITOR CELL POPULATION | FOX, ALLISON M | 1633 | DP | Non-Final OA | — | Pending | Jan 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialViaCyte Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Allison M Fox has the most, with 1 of ViaCyte Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
